Inhibitor Therapeutics, Inc. (INTI)
Stock Price: $0.0750 USD
0.0000 (0.00%)
Updated May 7, 2021 9:30 AM EDT - Market closed
| Market Cap | 28.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.26M |
| Shares Out | 371.93M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $0.0750 |
| Previous Close | $0.0750 |
| Change ($) | 0.0000 |
| Change (%) | 0.00% |
| Day's Open | 0.0750 |
| Day's Range | 0.0750 - 0.0750 |
| Day's Volume | 0 |
| 52-Week Range | 0.0300 - 0.1500 |
News
There are no news available yet.
About INTI
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed... [Read more...]
| Industry Biotechnology | Founded 1992 |
| CEO Nicholas Virca | Employees 1 |
| Stock Exchange OTCMKTS | Ticker Symbol INTI |